Aberrant methylation of CpG islands in the NOL4 gene promoter has been reported to be associated with 85% of the cervical cancer patients (16) and 91% of head and neck squamous cell carcinoma (HNSCC) (17). The gene discussed is NOL4; the disease is cervical carcinoma.